N-(1-PHENYLETHYL)-2-NAPHTHALENESULFONAMIDE

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(1-PHENYLETHYL)-2-NAPHTHALENESULFONAMIDE
• 英文别名: N-(1-phenylethyl)naphthalene-2-sulfonamide
• 化学式: C₁₈H₁₇NO₂S
• 分子量: 311.404
• InChiKey: GUEFAYBPKATUKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  萘-2-磺酰胺 、 1-Phenylethanethiol 在 10-phenyl-9-(2,4,6-trimethylphenyl)acridinium tetrafluoroborate 作用下， 以 1,2-二氯乙烷 为溶剂， 以25 %的产率得到N-(1-PHENYLETHYL)-2-NAPHTHALENESULFONAMIDE
  参考文献：
  名称：

  硫醇光催化生成碳正离子及其在交叉亲核偶联中的应用

  摘要：

  本文代表的是一种简单的硫醇，被鉴定为光化学形成碳正离子的有效前体。由于硫基自由基快速转化为二硫化物，这不仅可以稳定生成的硫基自由基，还可以允许第二次电子转移形成碳正离子。所得的碳正离子，包括伯苄基碳正离子、仲碳正离子和叔碳正离子，可以与氮、氧和碳亲核偶联伴侣以及复杂的药物分子顺利偶联，同时在空气中形成元素硫。

  DOI：

  10.1021/acs.orglett.4c01261

文献信息

• METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND
  申请人：California State University, Fresno

  公开号：US20180093960A1

  公开（公告）日：2018-04-05

  This invention offers an effective method of decreasing expression of apolipoprotein E and increasing expression of at least one of either LDL-receptor protein or AbcA1 protein including selecting mammalian cells expressing apoE and at least one of either LDL-receptor protein or AbcA1 protein, contacting the mammalian cell with an effective amount of a compound having general formula (I) or general formula (II) in an amount sufficient to decrease expression of the apoE and increase expression of at least one of the LDL-receptor protein or the AbcA1 protein in the mammalian cell.

  这项发明提供了一种有效的方法，可以降低载脂蛋白E的表达，并增加至少一种LDL受体蛋白或AbcA1蛋白的表达，包括选择表达apoE和至少一种LDL受体蛋白或AbcA1蛋白的哺乳动物细胞，将哺乳动物细胞与通式（I）或通式（II）的化合物的有效量接触，其量足以降低apoE的表达并增加哺乳动物细胞中至少一种LDL受体蛋白或AbcA1蛋白的表达。
• TRP INHIBITORS AND USES THEREOF
  申请人：Ostertag Eric M.

  公开号：US20120148604A1

  公开（公告）日：2012-06-14

  The present invention, relates to methods including compounds, derivatives, antibodies, interfering RNA, biologies, polypeptides, dominant negative effectors, and their use in the treatment of neuropathic pain by inhibition of transient receptor potential (TRP) channels. In another embodiment, this invention relates to inhibitors, antagonists, and agonists of TRPC4. TRPC4 therapeutic agents and modulators include but are not limited to small molecule inhibitors, compounds, amino acid derivatives, polypeptides, RNA interference agents, natural chemicals, ligand derivatives, and ions. TRPC4 therapeutic agents and modulators are developed for the treatment of neuropathic pain, including but not limited to pain sensations such as nociception, hyperalgesia, allodynia, and loss of sensory function.